Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallium-68 ethylenediaminetetraacetic acid
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Inhalation
01
Overview
Gallium-68 ethylenediaminetetraacetic acid (68Ga-EDTA) is a radiopharmaceutical imaging agent used in positron emission tomography (PET). It consists of the positron-emitting radioisotope gallium-68 complexed with the chelating agent ethylenediaminetetraacetic acid (EDTA). As a metal-essential radiopharmaceutical, its pharmacokinetics are determined by the physical and chemical properties of the chelate complex rather than biological targeting. It is primarily excreted by the kidneys via glomerular filtration, making it a tool for renal imaging and the quantitative assessment of glomerular filtration rate (GFR). Historically, it was used to image brain tumors by identifying disruptions in the blood-brain barrier. More recently, it has been investigated as an inhaled aerosol for PET/CT lung ventilation scans to evaluate airway function and particle deposition in patients with obstructive pulmonary diseases like asthma and COPD.
- Other names
- gallium-68 EDTAgallium68 EDTAgallium 68 EDTAGa-68 EDTA aerosolGa68 EDTA aerosolGa 68 EDTA aerosol
Beyond the preview
Go deeper on gallium-68 ethylenediaminetetraacetic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallium-68 ethylenediaminetetraacetic acid.